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1. Introduction 
Over the last few decades the prevalence of diabetes has dramatically grown in most regions 
of the world. In 2010, 285 million people had diabetes and it is estimated that the number 
will increase to 438 million in 2030 (1). About 5-10% of them have type 1 diabetes. 
Both types of diabetes are characterized by a progressive decline of pancreatic beta cell 
function and mass. In type 1 diabetes, the chronic autoimmune process causes the selective 
destruction of insulin-producing beta cells by the auto-reactive T cells in genetically 
predisposed individuals. There is a continuous loss of functional C-peptide responses and at 
the time of clinical presentation the beta cell mass is reduced by 70–90 %, as suggested by 
anatomic studies (2, 3). This results in an inability to secrete sufficient amounts of insulin 
and loss of metabolic control. As a consequence, exogenous insulin replacement in the form 
of multiple subcutaneous injections or continuous subcutaneous insulin infusions (CSII) is 
essential for patients with type 1 diabetes. It prevents death from acute metabolic 
complications and assures normal growth and development, maintenance of 
normoglycemia and prevention of end-organ complications. 
Type 2 diabetes results from an entirely different pathophysiological process. It is 
characterized by an increased resistance to insulin action in the peripheral tissues with 
decreased glucose uptake and enhanced hepatic glucose output associated with impaired 
insulin-secretory capacity caused by a progressive decline of beta cell function over time. 
Studies indicate a substantial loss of beta cell mass (of about 25-60 %) by the time of 
diagnosis, mainly secondary to increased apoptosis and impaired augmentation of cell mass 
through neogenesis (4, 5). The clinical onset is due to the reduction of beta cell mass per se 
and to a concomitant dysfunction of residual beta cells (6, 7). The beta cell failure, which 
seems to occur much earlier during the natural history of the disease than previously 
thought, results in significant insulin deficiency and by then, insulin administration is 
required in order to achieve glycemic control (8, 9). 
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2. Intensive insulin regimens: Evidence for benefit 
It is well established that in patients with both types of diabetes obtaining a good metabolic 
control is of paramount importance because the risk of developing chronic micro- and 
macrovascular complications is dependent on the degree of glycemic control (10). Current 
guidelines from professional organizations recommend achieving glycated hemoglobin 
(HbA1c) levels lower than 7% (and closer to normal values in selected individuals, if this 
could be achieved without significant increase in hypoglycemic events or other side effects) 
(11). Several landmark studies emphasize the importance of more physiologic insulin 
profiles in reaching these goals. 
The Diabetes Control and Complications Trial (DCCT) proved that tighter glycemic control 
after onset obtained with intensive insulin regimens can prevent / delay microvascular 
complications in patients with type 1 diabetes compared with conventional insulin regimens 
(12). The follow-up of the DCCT, the Epidemiology of Diabetes Interventions and 
Complications (EDIC) study provided evidence for the sustained benefit in subjects with 
prior intensive treatment, even if during the follow-up period the glycemic control was 
similar to that of subjects previously receiving conventional therapy (13-16). These studies 
demonstrated that the risk of developing long-term complications is determined both by the 
degree and the total duration of glycemic exposure. In addition, the DCCT established the 
relationship between glucose control and residual beta cell function as subjects with 
stimulated C-peptide concentrations > 0.2 pmol/ml had better outcomes (17, 18). The 
maintenance of endogenous beta cell function was associated with diminished disease 
progression, improved long term metabolic control and reduced chronic complications. 
These studies highlighted the role of insulin therapy over long-term. 
In patients with type 2 diabetes similar benefits of intensive insulin regimens have been 
shown. In the Kumamoto study, which included a smaller patient population, intensive 
glycemic control obtained by multiple insulin injection therapy delayed the onset and 
progression of the early stages of diabetic microvascular complications (19, 20). Likewise, 
the United Kingdom Prospective Diabetes Study (UKPDS) emphasized the role of glycemic 
control in reducing the incidence of chronic complications in patients with type 2 diabetes, 
although in this study the intensive treatments were not limited to insulin regimens (21-23). 
Similar to EDIC, the follow-up of the UKPDS cohort showed the persistence of 
microvascular benefits in patients formerly treated with intensive regimens (24). A more 
recent study in subjects with newly diagnosed type 2 diabetes demonstrated that transient 
intensive insulin therapy (with continuous subcutaneous insulin infusion or multiple daily 
insulin injections) resulted in favorable outcomes on glycemic control and beta cell function 
compared to oral hypoglycemic agents (25). Trials in patients with type 2 diabetes of longer 
duration have also supported the benefits (even if more modest) on the onset / progression 
of chronic complications (26-28). 
3. The importance of controlling postprandial hyperglycemia and 
hypoglycemic events 
To date, the therapeutic interventions have mainly been focused on lowering HbA1c with 
emphasis on fasting blood glucose levels. However, in order to obtain optimal glycemic 
control with HbA1c levels < 7%, controlling both fasting and post-meal glycemia is 
necessary (29, 30).  
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It is well established that poorly controlled diabetes is associated with development of 
chronic micro- and macrovascular complications. Experimental studies demonstrated the 
atherogenic role of postprandial glycemic peaks and the link between the post-meal or post-
challenge hyperglycemia (2hPG) and cardiovascular morbidity and mortality. Two meta-
analyses have shown an exponential relationship between incidence of cardiovascular 
events and fasting glucose or 2hPG (31, 32). The relationship was stronger and highly 
significant for 2hPG and there seemed to be no threshold for 2hPG. Several population-
based studies have basically confirmed this finding indicating an increased relative risk (in 
the range of 1.18 to 3.3) of cardiovascular or coronary heart disease mortality in patients 
with increased 2hPG (33). It has been reported that in individuals with type 2 diabetes, 
especially women, postprandial plasma glucose is a stronger predictor of cardiovascular 
events than fasting glucose levels (34). Another study indicated that both fasting and post-
meal glycemia were predictive for cardiovascular events after adjusting for other risk factors 
in type 2 diabetic subjects (35). 
A growing body of evidence shows that there is a relationship between postprandial 
hyperglycemia and markers of cardiovascular disease such as oxidative stress, carotid IMT 
and endothelial dysfunction. Oxidative stress has been implicated as a cause of both macro- 
and microvascular complications of diabetes. The proposed mechanism is that hyperglycemia, 
insulin resistance and free fatty acids feed into oxidative stress, activation of RAGE and PKC, 
which leads to vascular inflammation, thrombosis and vasoconstriction (36). Furthermore, 
increased risk of retinopathy, certain cancers and cognitive dysfunction in elderly was shown 
to be associated with postprandial hyperglycemia in type 2 diabetic patients (37-39).  
The Kumamoto study demonstrated that postprandial glycemia was strongly associated 
with onset of retinopathy and nephropathy (as were fasting blood glucose and HbA1c) and 
that control of both fasting glucose levels < 110 mg/dl and post-meal glucose levels < 180 
mg/dl prevented the onset and progression of diabetic microvascular complications (19, 20).  
On the other hand, the cost of strict glycemic control and intensive therapy is an increased 
risk of hypoglycemia, which per-se is a limiting factor in achieving long-term near-normal 
glucose control in patients with diabetes (40). Depending on its degree, hypoglycemia can 
affect physical and cognitive functions and can induce negative psychological and social 
consequences (41). Studies have consistently indicated a higher rate of hypoglycemia in 
patients with type 1 diabetes treated to lower HbA1c targets (40, 42). In the DCCT, the 
frequency of severe hypoglycemia was three times higher in subjects treated with intensive 
insulin therapy compared with those on conventional therapy, while in the Stockholm 
Diabetes Intervention Study - severe hypoglycemia occurred 2.5 times more frequently in 
the intensively treated group (43, 44). Insulin-treated subjects with type 2 diabetes 
experience severe hypoglycemia less frequently than patients with type 1 diabetes. This fact 
is explainable in part by the maintenance of some beta cell function (which allows a decrease 
of insulin secretion when blood glucose falls) and by insulin resistance (41). However, data 
from UKPDS provide evidence that the risk of hypoglycemia increases with longer duration 
of insulin treatment. Another study reported similar frequencies of severe hypoglycemia in 
patients with type 2 and type 1 diabetes after matching for duration of insulin therapy (45, 
46). It is plausible that in real life patients on intensive insulin regimens experience higher 
rates of hypoglycemia, but since there is relatively limited data on the actual frequency of 
asymptomatic and mild hypoglycemia, episodes of mild hypoglycemia may be 
underestimated and/or underreported (41).  
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Hypoglycemia, even mild (especially if it occurs recurrently), can be associated with negative 
effects, such as impaired autonomic counter-regulation, compromised behavioral defenses 
against subsequent decreasing glucose concentrations and hypoglycemia unawareness, which 
causes a vicious cycle of recurrent hypoglycemia (41, 47). Severe hypoglycemia may exert even 
more serious side effects, such as seizures, unconsciousness (which may be particularly 
debilitating in the elderly), coma and even death (48). In older patients with type 2 diabetes 
and a history of severe hypoglycemia, an increased risk of dementia has been reported, 
particularly for patients who have a history of multiple episodes (49). In the UKPDS, recurrent 
hypoglycemia was associated with decreased quality of life in patients treated with insulin 
(50). Moreover, the unpleasant symptoms and negative consequences of hypoglycemia may 
result in fear and anxiety, lower treatment satisfaction, which in turn may negatively impact 
the diabetes management and adherence to therapy, precluding a full attainment of the 
benefits offered by improved glycemic control (48).  
Evidence exist that hypoglycemic episodes, especially severe ones, are associated with 
adverse cardiovascular events (such as prolongation of the QT interval, cardiac arrhythmias, 
sudden cardiac arrest, and acute myocardial infarction), which are triggered by the 
stimulation of the sympathetic nervous system and the catecholamine surge (51, 52). 
Hypoglycemia also has proinflammatory consequences that may augment the risk of plaque 
inflammation and rupture, causing subsequent cardiovascular events (51). Hypoglycemia, 
mainly the recurrent and severe episodes, and the presumed ensuing cardiovascular toxicity 
may increase the susceptibility to poor cardiovascular outcomes, especially in subjects with 
significant atherosclerosis and functional / structural heart abnormalities. The cause of 
excess mortality during intensive therapy seen in the ACCORD study is not entirely clear, 
but it is thought that the most plausible cause is iatrogenic hypoglycemia (51). 
Thus, it is equally important to avoid both hyperglycemic surges and hypoglycemic events 
while striving to obtain a tight metabolic control.  
4. Restoring physiological insulin secretory profiles 
In the normal, physiologic conditions there is a low basal insulin output that suppresses 
endogenous hepatic glucose production (overnight and between meals) as well as 
incremental responses of insulin secretion following food ingestion.  
After a meal, blood glucose concentrations start rising within 15 minutes, reach a peak at 
about 30-45 minutes and within 1-2 hours return to basal levels and remain stable until the 
next food ingestion (53, 54). The maximal amplitude of glucose excursion depends on the 
amount and type of carbohydrates ingested (53). These dynamics are mirrored by the 
prandial insulin secretion profile: there is an initial (first) phase, which peaks in 2-3 minutes 
and lasts about 10 minutes, then there is a second phase of insulin release that becomes 
apparent after 10 minutes and continues as long as the glucose concentrations remain 
elevated and is concordant with the amount of carbohydrates absorbed (54-56). Once the 
blood glucose levels decrease, insulin secretion returns to baseline values, in order to 
prevent hypoglycemia in the post-absorptive phase (56).  
It is believed that insulin regimens that best mimic the physiological pattern of insulin 
production are most likely to reach near-normal glycemic control by regulating both fasting 
and postprandial blood glucose levels (56, 57). These regimens require a sharp increase of 
insulin levels after meals and flat, nearly constant plasma insulin concentrations in the 
postabsorbtive / interprandial periods. They are known as basal-bolus therapy because they 
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attempt to replicate the normal insulin secretion by combining basal and meal-time insulin 
replacements (58).  
The “gold-standard” of insulin replacement is CSII by means of a pump, which delivers short-
acting insulin in a continuous manner at determined rates and assures a peakless insulin 
profile between meals and insulin surges at meal-time (56, 58). The short-acting insulin 
analogues are better suited for CSII because of their faster absorption from subcutaneous 
tissue (59). The basal insulin rates can be adjusted on an hourly basis according to blood 
glucose oscillations to meet the 24-hour requirements of each individual and should provide 
about half of the total daily dose. The prandial doses are calculated by the patients and 
delivered according to blood glucose monitoring results, target glucose levels, carbohydrate 
content of the meal, physical activity, insulin sensitivity and other factors (58). Several studies 
have shown that CSII offers more flexibility and provides better glycemic control with 
improved HbA1c levels and fewer hypoglycemic events due to lower variability and better 
reproducibility of insulin absorption (probably resulting from the fact that the subcutaneous 
insulin depot is smaller) (60, 61). However, the cost of such therapy is too high to be widely 
available and it also requires significant patient involvement, education and motivation. 
Alternatively the basal/bolus replacement can be supplied in the form of multiple daily 
injections. Traditionally, the regimens consisted of two injections of NPH (in the morning 
and at bedtime) plus 2-3 injections of regular insulin with meals. The problem with the 
intermediate-acting insulin preparations like NPH is that their pharmacokinetic profile does 
not provide a physiologic basal replacement: they have a peak at about 4-6 hours post 
subcutaneous injection and the action wanes rapidly at about 5-6 hours after the peak (56, 
58). This profile increases the risk of nocturnal hypoglycemia (even with a bedtime snack 
intake), because at the time of their highest concentration (which usually occurs between 
midnight and 2-3 a.m.) the insulin sensitivity is higher and patients would require less basal 
insulin (56). Nocturnal hypoglycemia is a serious concern because it causes morning 
hyperglycemia through the release of counter-regulatory hormones (glucagon, epinephrine, 
growth hormone, cortisol) and prolonged insulin resistance and influences different 
physical and psychological functions during the following day. In addition, undetected 
nocturnal hypoglycemic episodes contribute to hypoglycemia counter-regulatory failure 
and unawareness, which in turn predisposes to severe hypoglycemia and profoundly 
impacts on patients’ quality of life (62). On the other hand, the time-action profile of the 
intermediate-acting insulin poses another problem: during the morning hours (after 4 a.m.) 
the requirement for basal insulin is greater due to increased release of counter-regulatory 
hormones and by then the insulin action is waning, which results in morning 
hyperglycemia. An attempt to correct this by increasing the bedtime insulin dose may result 
in higher risk of nocturnal hypoglycemia.  
A different approach of multiple daily injections which attempts to alleviate these problems 
uses short-acting insulin analogues at meal-time with one or two injections of long-acting 
insulin analogues (glargine or detemir) and it is the preferred regimen in recent years (58). 
The long-acting analogues afford less glycemic fluctuations, less variability, reduced risk of 
hypoglycemic events and a significantly prolonged duration of action (17-24 hours) due to a 
steady absorption into the circulation and more stable serum concentrations (63, 64). Studies 
have indicated fewer overall, nocturnal and severe hypoglycemic episodes in both types of 
diabetes (especially in type 1), while providing similar or slightly improved metabolic 
control compared with NPH insulin (65-67). 
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5. The limitations of current prandial insulin treatment for type 1 and type 2 
diabetes  
Multiple daily insulin injections are the mainstay of insulin delivery for many patients with 
type 1 diabetes and patients with type 2 diabetes that cannot be controlled with other 
regimens, especially those with longer duration of the disease and severe insulin deficiency. 
Despite the evidence and increased awareness of the necessity to achieve strict glycemic 
control, current insulin therapy has some limitations that preclude reaching the goal of 
maintaining near-normal glycemia in the long-term, even in compliant patients. The major 
challenges are related to avoiding postprandial hyperglycemia and late hypoglycemia, 
which are mainly caused by the mismatch between the time-action profile of the 
administered insulin and postprandial glucose excursions.  
The “conventional” prandial insulin therapy with regular human insulin has its 
shortcomings in terms of the pharmacokinetic properties which limit their clinical efficacy: 
the onset of action is slow, the peak is reached in about 2-3 hours and the total duration of 
action lasts 5-8 hours (68). This is caused by the fact that the dissociation rate of human 
insulin from hexamers into monomers in the subcutaneous tissues is slow and the 
absorption into the bloodstream is gradual. Thus, the maximal insulin concentrations do not 
occur at the time when glucose levels are the highest, and so the short-acting insulin has to 
be administered 30-45 minutes before meals in order to minimize postprandial 
hyperglycemia. This is quite inconvenient for patients (and poses a risk of pre-meal 
hypoglycemia if the food intake is inadvertently delayed) and even so, the time-action 
profile is not optimal. Glycemic excursions are not properly covered and 4-5 hours post-
injection, after the food absorption is completed, there is still some insulin absorption from 
subcutaneous depot (58). This results in relative hyperinsulinemia, which increases the risk 
of late postprandial hypoglycemia and would require a snack intake to prevent it. 
Moreover, the regular human insulin preparations have important intra- and inter-
individual variations that result in unpredictable effects and makes it even more difficult to 
avoid hyper- and hypoglycemia (69). 
In order to overcome the problems of non-physiologic pharmacokinetics, the regular human 
insulins have been largely substituted with the newer insulin analogues that were 
developed by means of protein engineering and recombinant DNA technology to enable 
better glycemic control by faster action (70). The insulin analogues have been obtained by 
substitution or minimal alterations in the amino acid sequence in regions of the molecule 
not essential for binding to the insulin receptor but pivotal for dimer formation in order to 
diminish the tendency of self-association between insulin molecules and allow a faster 
absorption from injection site (70). There are three rapid-acting insulin analogues available 
at the moment: insulin lispro (based on amino-acid substitution of proline at position B28 
and lysine at position B29), insulin aspart (with aspartic acid substituted for proline at 
position B28) and insulin glulisine (that has an asparagine to lysine substitution at position 
B3, and a lysine to glutamine acid substitution at position B29) (71). Despite the differences 
in structure, the three analogues have similar pharmacokinetic and pharmacodynamic 
properties (70). Their onset of action is more rapid, which permits an administration within 
10-15 minutes before meals, the peak is greater and occurs at about 1-2 hours and the total 
duration of action is shorter (4-5 hours) compared to regular human insulin (Table 1) (58, 
68). This allows an improved replacement of mealtime insulin needs with regards to 
postprandial plasma glucose control and more flexibility than regular insulin. In addition, 
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the insulin analogues have a smaller intra- and inter-individual variability compared to 
regular insulin which could provide a somewhat improved glycemic control and potentially 
reduced risk of hypoglycemia (69).  
 
Insulin  Onset of action Peak action Total duration of action 
Short-acting 
Regular 30-45 min 2-3 h 5-8 h 
Rapid-acting 
Lispro 
Aspart  
Glulisine 
5-15 min 1-2 h 4 h 
Table 1. The pharmacodynamic profiles of currently available prandial insulin formulations 
(68) 
However, even with the insulin analogues the synchronization between insulin action and 
glucose absorption from a meal is still less than ideal, as they do not replicate normal 
physiology, and many patients still have suboptimal glucose control. Several meta-analyses 
have suggested that insulin analogues offer rather modest or inconsistent clinical advantages 
over conventional insulin in terms of lowering HbA1c and reducing hypoglycemia, in children 
and adults with type 1 diabetes (72-76). Data on the influence on hypoglycemia is particularly 
inconsistent. Some studies have shown that in fact the overall frequency of hypoglycemic 
episodes were similar with analogue insulin and regular insulin use in adults with type 1 
diabetes and were modestly decreased in children (72-77). Moreover, some reports indicated 
that the frequency of severe and nocturnal hypoglycemia seemed to be reduced with 
analogues in adults, but not in prepubertal children, while others found no difference in the 
frequency of severe or nocturnal hypoglycemia and no evidence for reduction in patient 
awareness for hypoglycemia with insulin analogues (72-78). It should be noted that  
hypoglycemia occurrence is not fully attributable to the pharmacokinetic profile of the insulin 
preparations, but may also result from a mismatch between insulin dose and the carbohydrate 
content of the meal, delayed food intake or other factors (79).  
On the other hand, postprandial hyperglycemia still occurs with the new insulin analogues 
(80, 81). Hyperglycemic postprandial glucose excursions were found to reach levels over 300 
mg/dl in about 50% and over 180 mg/dl in almost 90% of children with type 1 diabetes 
with good overall metabolic control (82). The findings were confirmed by other studies that 
indicated postprandial glucose levels higher than 300 mg/dl in subjects with type 1 diabetes 
receiving multiple insulin injection therapy (83). Targeting postprandial hyperglycemia is 
important in order to improve HbA1c levels and this has also been recently highlighted by 
the International Diabetes Federation guidelines (84, 85).  
In everyday life the control of postprandial hyperglycemia poses even more challenges due 
to variations in dietary intake and physical exercise or insulin dosage and timing changes 
(patients may modify the timing of insulin administration in the sense of dosing 
immediately before or even after meals in order to fit their lifestyle / daily activity 
requirements) (86). In addition, lack of predictable insulin response may occur with insulin 
analogues because their absorption can be affected by various factors such as: mechanics of 
injection, the injection site, and metabolic factors, similar to regular human insulin (87). 
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Two meta-analyses indicated that regular human insulin and rapid-acting analogues have 
comparable frequencies and types of adverse events (other than hypoglycemia), i.e. local site 
reactions, ketoacidosis and the discontinuation rates during the clinical studies were similar 
for the two types of insulin preparations (75, 77). 
6. Current ultrafast insulin formulations 
Thus, the limitations of current insulin formulations and the need for proper postprandial 
glycemic control have led to research of novel, ultrafast insulin formulations /delivery 
systems that could eventually better match post-prandial glucose excursions (by speeding 
the onset of insulin absorption and action coupled with a faster offset of action) and that 
would offer improved flexibility in terms of injection time relative to a meal (Table 2). By a 
closer approximation of the normal insulin release, several outcomes could be obtained, i.e. 
improvement of HbA1c through a better control of postprandial blood glucose, reduced 
incidence of late-phase hypoglycemia, lower intra-subject variability, and less weight gain.   
Recently, stainless steel microneedle syringe devices have been under investigation for 
intradermal delivery of insulin and their potential to improve postprandial glycemia has 
been evaluated. The microneedles (34-gauge; an external diameter of approximately 260 μm, 
1.25-1.75-mm long) penetrate the stratum corneum and epidermis to reach the dense beds of 
capillaries and lymphatic vessels of the dermis (88). The dermis layer can facilitate a faster 
insulin absorption compared to injection into the subcutaneous layer by an increased 
lymphatic absorption and reach blood circulation.  
 
Insulin  
Onset  
(early T50%) 
Peak  
(T GIRmax) 
Offset  
(late T50%) 
Intradermal90 28-35 min 105-110 min 271-287 min 
rHUPH20+insulin93 43-44 min 72-114 min 119-275 min 
VIAject95 31-35 min 111-136 min 270-297 min 
InsuPatch101 NA 95 min NA 
Technosphere105,106 NA 42-79 min NA 
Oral-lyn119-121 23-35 min 40-50 min 56-101 min 
Table 2. The pharmacodynamic profiles of ultrafast insulin formulations / delivery systems 
under development 
In animal models the intradermal delivery of insulin by microneedles provided a unique 
pharmacokinetic profile more closely resembling the intravenous rather than the 
subcutaneous administration (89). The profile is characterized by an extremely rapid uptake 
and systemic distribution from the injection site: the time to maximum concentration was 
significantly reduced (with 64%) for insulin lispro administered intradermaly vs. 
subcutaneously. In addition, the maximum circulating peak concentrations were elevated 
several fold (349% for insulin lispro) compared to subcutaneous delivery. Moreover, both 
regular and analogue insulins, despite their differences in molecular weight, when delivered 
by microneedles showed a more rapid onset of action than subcutaneous delivery of insulin 
analogue (lispro) (89).  
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A clinical study in healthy volunteers that evaluated the pharmacokinetics and 
pharmacodynamics of intradermal administration of insulin lispro compared to 
subcutaneous injections under euglycemic clamp conditions, has basically confirmed these 
findings (90). Delivery via microneedles resulted in faster insulin uptake with decreased 
time to maximal insulin concentration (by approximately 24 minutes), higher relative 
bioavailability at early post-injection times and a more physiologic metabolic effect, with 
faster onset of action (shorter times to maximal and early half-maximal glucose infusion 
rates) and more rapid offset of action (shorter time to late half-maximal glucose infusion 
rates) (90). Another clinical study was conducted in patients with type 1 diabetes in order to 
determine if the more rapid absorption of insulin resulting from microneedle administration 
translates into a significant reduction in postprandial glucose levels under standardized 
meal conditions (91). The results indicated that postprandial glucose levels were improved 
when regular human insulin was delivered intradermaly vs. subcutaneously, but were 
similar for analogue insulin. In clinical studies the intradermal delivery was generally well 
tolerated (although some transient, localized wheal formation and redness were noticed at 
injection sites), but the potential effects of high level or repetitive exposure of protein drugs 
such as insulin on the lymphatics and immune system need full investigation (90, 91).  
Another area of research focuses on the combination of available insulin products with a 
human recombinant hyaluronidase, which facilitates the local dispersion and absorption of 
co-administered molecules (92, 93). The human recombinant hyaluronidase is a highly 
purified neutral pH-active enzyme that depolymerizes hyaluronan in the hypodermis under 
physiologic conditions. Thus, it decreases the resistance to fluid flow and further contributes 
to the drug dispersion for better exposure to a larger capillary network (92). Following this, 
concomitant injection with proteins / drugs such as insulin, is expected to lead to an 
enhanced absorption and improved bioavailability. Recombinant human hyaluronidase 
(rHuPH20) is a genetically engineered soluble hyaluronidase approved by the Food and 
Drug Administration as an adjuvant to enhance permeation of other injected drugs (94). 
Since rHuPH20 is rapidly metabolized locally, without systemic exposure and because 
hyaluronan has a fast turn-over, the permeation effects are transient (94).  
A phase 1 glucose clamp study in healthy volunteers evaluated the insulin time-
concentration curve and pharmacodynamic profiles of insulin analogue (lispro) and of 
regular human insulin combined with rHuPH20 and reported significantly faster systemic 
absorption, enhanced insulin plasma concentrations and faster metabolic effects compared 
with either insulin formulation alone (95). A rise in insulin concentration was observed 
within 3 minutes following the injection and the enhanced pharmacokinetic and 
glucodynamic effects early after injection were accompanied by reduced late effects. A 
second study in healthy subjects also reported a lower intra-subject variability with 
rHuPH20 coadministration (94). A phase 2 standardized meal-test study in patients with 
type 1 diabetes examined whether the accelerated insulin absorption has favorable 
consequences on the control of postprandial glycemic excursions (94). As in the phase 1 
studies, the coadministration of rHuPH20 with regular insulin or lispro yielded an 
accelerated insulin concentration profile that was accompanied by a significant reduction in 
both mean peak and total post-meal glucose concentrations compared to either insulin 
alone. Post-meal hypoglycemia was reported to be generally mild and the overall 
hypoglycemic risk comparable for lispro with or without rHuPH20 and reduced for regular 
insulin with rHuPH20 compared with regular insulin alone (94). Clinical studies reported a 
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good tolerability profile without severe adverse effects, but there is no safety data so far 
regarding the repeated or long term exposure to recombinant hyaluronidase. 
A third novel ultrafast insulin formulation, VIAjectTM, is currently under clinical 
development. The main concept of the approach is that instead of altering the structure of 
insulin molecule, the zinc ions are pulled away from human insulin hexamers and 
simultaneously charges on the surface of the insulin molecule are masked by the addition of 
ethylene diamine tetraacetic acid and citric acid (96). This results in destabilization and 
dissociation of the insulin hexamer and prevents re-association to the hexameric state after 
subcutaneous injection.  
A glucose clamp study in healthy volunteers evaluated the pharmacodynamic, 
pharmacokinetic and the dose-response properties of the VIAject in comparison with 
regular human insulin and insulin lispro (96). The results indicated a more rapid increase 
and decline in serum insulin concentrations after VIAject injection compared to regular 
human insulin and insulin lispro, but the difference between the later and VIAject failed to 
reach statistical significance (96). The three dose of ultrafast insulin used in the study 
showed a linear dose-response relationship. The time-action profile induced by VIAject was 
faster than either subcutaneously injected human insulin or lispro, with a more rapid onset 
of action and maximal metabolic activity, while the activity in the first 2 hours after injection 
was higher. A second glucose clamp study in patients with type 1 diabetes confirmed the 
faster absorption kinetics and the more rapid onset of insulin action compared to regular 
human insulin and showed that upon repeated administration, the within-subject variability 
is lower than that of human insulin (97). Moreover, a more recent meal-test study conducted 
in patients with type 2 diabetes indicated that treatment with VIAject determined a 
significant decrease of postprandial oxidative stress and improved endothelial function 
compared with regular insulin or insulin lispro, while all insulin formulations resulted in 
comparable improvements in central arterial elasticity (98).  
Another innovative approach developed in order to accelerate insulin absorption into the 
bloodstream is using a technology (InsuPatchTM) that heats the tissue locally around the 
injection site (99). Changes in temperature at injection site are partially responsible for 
variability in insulin absorption (87). Increased skin temperature results in vasodilatation 
and improved local perfusion, which enables accelerated and enhanced insulin absorption 
(100).  The InsuPatchTM device is an add-on to the insulin pump and is comprised of a 
heating pad attached to an insulin infusion set and a controller that monitors the 
temperature of the pad (99). The heating pad warms in a controlled manner the tissue 
surrounding the injection site for 30 minutes after insulin delivery, without heating the 
insulin itself. 
A study using a meal tolerance test in subjects with type 1 diabetes treated by CSII tested the 
effect of InsuPatchTM on rapid-acting insulin absorption and post-challenge glucose 
excursions. The study found a significant effect of the heating device on the 
pharmacokinetic parameters: the maximum insulin concentrations increased (by 38%), as 
well as the total insulin absorption during the first 30, 60 and 90 minutes, (by 57%, 45% and 
27%, respectively) as measured by area under the curve (AUC). The time to maximal 
concentration and time to half maximal concentration significantly decreased, indicating an 
accelerated insulin absorption. The changes were accompanied by significant reductions in 
post-challenge glucose levels (both 90 minutes post-meal glucose excursion and AUC 0-120 
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minutes of glucose concentrations were lowered” before by 39%) (99). The InsuPatchTM 
was also tested in youth with type 1 diabetes using a euglycemic clamp procedure. The use 
of the InsuPatchTM was found to decrease time to peak action by more than 40 minutes, 
whereas the bioavailability and peak responses remained unchanged (101, 102). Such 
improvements in time-action responses may provide a better control of post-meal glucose 
excursions (101). Another study that evaluated the effect of the InsuPatchTM heating device 
on postprandial blood glucose levels after different standardized meals in patients with type 
1 diabetes on CSII has confirmed that local heating of the skin around the infusion site 
significantly increases early post-delivery insulin levels (AUC 0-60 minutes for insulin 
concentrations above baseline) as well as significantly reduces post-prandial blood glucose 
(blood glucose at 90 minutes and AUC 0-120 minutes of blood glucose levels) without 
causing more hypoglycemia (103). Current efforts are being employed in order to optimize 
the effect of the device on the pharmacokinetic and pharmacodynamic parameters by 
improving the heating process. The InsuPatchTM device was well tolerated and no serious 
adverse effects were reported with its use to date (99). 
A different strategy that attempts to overcome the barriers and limitations of subcutaneous 
insulin administration is engaging a diverse route of delivery (i.e. pulmonary). After the 
discontinuation of the first inhaled insulin product (Exubera), the development of most of the 
pulmonary administration systems has ceased.  One of them though, TechnosphereTM insulin, 
is still being developed and it appears to overcome some of the barriers that contributed to the 
withdrawal of Exubera (104, 105). Technosphere™ insulin is an ordered lattice array 
containing recombinant human insulin, formulated as a crystalline dry powder. The 
TechnosphereTM carrier is created with microcrystallized plates of fumaryl diketopiperazine 
that undergo self-assembly into microparticles with a very large surface area and a high 
internal porosity which are then lyophilized into a dry powder (104). Insulin is absorbed onto 
the surface of the particles and is delivered by a high-impedance, low-flow, breath-powered 
inhaler with a powder de-agglomeration mechanism that allows for a high percentage of the 
administered insulin to be absorbed. At the neutral pH environment of the lungs, the 
microparticles dissolve rapidly and insulin is absorbed across the pulmonary epithelium into 
the systemic circulation, while the carrier is cleared unmetabolized (104, 106). 
The pharmacokinetic clamp studies performed in healthy volunteers and patients with type 
2 diabetes revealed a very rapid systemic insulin uptake (time to maximal insulin 
concentration around 15 minutes) with a subsequent fast onset of action (time to maximal 
metabolic effect of about 40-80 minutes) and a short duration of action (106-109). These 
characteristics had basically been confirmed by a meal-test study in patients with type 2 
diabetes, which demonstrated a more rapid absorption and higher peak insulin levels as 
well as markedly improved postprandial glycemic control with the inhaled insulin 
compared with subcutaneous regular human insulin (110). A linear systemic insulin uptake 
profile was noted in studies employing healthy volunteers inhaling three doses of insulin 
(106-108). In addition, the within-subject variability of insulin exposure following inhalation 
of Technosphere™ insulin was lower compared to regular insulin (109). The relative 
bioavailability was reported to be 26-50% in the first 3 hours after administration (111). 
Given that other inhaled insulin preparations have been associated with reduced absorption 
in patients with chronic obstructive pulmonary disease, a study assessing the 
pharmacokinetic profile and safety of Technosphere™ insulin in nondiabetic patients with 
chronic obstructive pulmonary disease has shown that insulin absorption was not 
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significantly altered in this group (112). Similarly, the absorption of inhaled insulin 
appeared not to be altered in a clinically significant manner in smokers (105). 
The clinical efficacy of Technosphere™ insulin was assessed in studies of 11 or 12 week-
duration in patients with type 2 diabetes (either insulin-naive or treated with basal insulin 
glargine), which demonstrated significant reductions in postprandial glucose excursions as 
well as clinically meaningful improvement of glycemic control as evaluated by HbA1c (113, 
114). Moreover, a study of longer duration (52 weeks) in subjects with type 2 diabetes 
compared the inhaled insulin plus insulin glargine with twice daily biaspart insulin and 
indicated that changes in HbA1c determined by the treatment with inhaled insulin were 
similar and non-inferior to that with biaspart insulin (115). In addition, the weight gain and 
the incidence of both mild-to-moderate and severe hypoglycemic events were lower with 
inhaled insulin therapy.  
Considering the issues associated with Exubera in the past, patient satisfaction and 
acceptance has been evaluated with the new inhaled insulin product. Overall, significant 
improvements in attitudes toward insulin therapy, treatment satisfaction, and treatment 
preference were reported with Technosphere™ insulin (105, 116). The therapeutical 
approach using the new inhaled insulin was implemented without a negative impact on 
health-related quality of life (116). 
To date, Technosphere™ insulin has demonstrated a favorable safety and tolerability profile 
in clinical studies that collected data in healthy volunteers and patients with diabetes (105). 
The most frequent treatment-emergent adverse events associated with inhaled insulin in 
clinical studies were cough and hypoglycemia. Weight gain is commonly associated with 
insulin therapy. However, data so far indicated that with Technosphere™ insulin the weight 
gain was actually less compared with subcutaneous prandial insulins (105). While there are 
no reports of lung cancer or other serious side effects associated with Technosphere™ 
insulin to date, longer-term safety follow-up and evaluation should be done in subjects 
treated with this inhaled insulin formulation, especially in smokers and in subjects with 
respiratory disorders. 
Finally, another alternative approach of insulin delivery is through the oral (buccal) route, 
which offers some advantages: good accessibility, high level of vascularization, relatively large 
surface for absorption (100–200 cm²), avoidance of presystemic metabolism in the liver, 
robustness, direct contact of the drug with the mucosa, weak variations of pH (117, 118). Oral-
lyn is a liquid formulation of human regular insulin with very small amounts of generally 
regarded as safe (GRAS) ingredients, which is delivered to the buccal mucosa with a metered-
dose, slightly modified asthma-like spray and used for prandial insulin therapy (117). The 
device spray the uniform-sized insulin droplets with high speed (100 mph) into the mouth, 
which then penetrate the superficial layers of the mucosa and get absorbed into the 
bloodstream. 
The pharmacokinetic and pharmacodynamic properties of Oral-lyn have been evaluated in 
a number of glucose clamp studies, which have demonstrated a significantly more rapid 
absorption (about 25 minutes) to higher levels than subcutaneous injection of regular human 
insulin and a rapid return to baseline values (90 minutes after application) (118-121). The 
profile was paralleled by the glucose infusion rates that reached maximal levels significantly 
earlier (at about 45 minutes) and then returned back to baseline concentrations after 
approximately 120 minutes. Increasing doses of Oral-lyn determined a linear dose-response 
relationship with respect to maximal insulin concentrations, while time to maximal insulin 
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levels was similar across doses (118-121). Additional meal-test studies indicated that the 30- 
and 60-min glucose levels were significantly lower with oral insulin spray treatment (122, 
123). The metabolic effects of Oral-lyn were evaluated in subjects with type 2 diabetes 
suboptimally controlled with oral hypoglycemic agents and showed that oral insulin spray 
significantly decreased the 2-hour postprandial glucose increments in comparison with the 
oral agents alone and that the difference was more pronounced at the end of the 4-h period, 
due to the rapid onset and wane of action of oral insulin spray (124). In all of the studies 
Oral-lyn was generally well tolerated, although some individuals experienced transient (1–2 
min), mild and self-limited dizziness during dosing with both the oral insulin and placebo 
spray (122-124). No other significant side effects (including severe hypoglycemia) were 
noted in studies involving subjects with type 2 diabetes (122). 
It should be mentioned that although some of the ultrafast insulin formulations / insulin 
delivery systems are in early phases of development and/or have not specifically reported 
for hypoglycemic events, based on their pharmacokinetic properties it can be reasonably 
expected that they may benefit patients with diabetes by reducing post-meal hyperglycemia 
with decreasing (or at least without increasing) the risk of hypoglycemic events. 
7. Conclusions 
The main goal of insulin therapy is to obtain a near-normal glycemic control by mimicking 
the time-action profile of physiologic insulin secretion as close as possible and with minimal 
side effects. Management of both types of diabetes is continually evolving as new therapies, 
including new insulins / insulin delivery systems are still emerging. In real life, with all 
progress of the recent years, all the above mentioned objectives are difficult to be reached 
and successful implementation of intensive diabetes management poses true challenges. 
Ideally, an insulin-replacement therapeutic approach would keep in check both the fasting 
and the postprandial glucose concentrations while attaining target HbA1c values, without 
high glycemic variations and without causing hypoglycemia. Current rapid-acting insulin 
analogues have a faster pharmacokinetics and action compared with regular human insulin 
following subcutaneous administration (Table 1). This allows improved control of the post-
meal early hyperglycemic surge and late relative hyperinsulinemia, the cause of 
postprandial hypoglycemia. However, recent meta-analyses showed that in fact the use of 
insulin analogues had only a modest impact on overall glycemic control and on the rates of 
side effects, mainly hypoglycemia, compared to conventional insulins (72-76). This is 
because although improved, the time-action profile still does not exactly replicate normal 
insulin secretion and therefore there is a mismatch with the blood glucose concentrations 
curve. Both postprandial hyperglycemia and hypoglycemia have important health 
consequences as well as on quality of life and failure to address them both may compromise 
the success of treatment in the short- and long-term.  
The extent to which these goals can be met depends on many factors, including the type of 
diabetes, the stage in the progression of the disease and the pharmacokinetic profile of 
insulin formulation. If some of these factors are unmodifiable, others are, and efforts are 
being employed to develop new, improved ultrafast insulin products / delivery systems. 
They provide even more rapid pharmacokinetic and pharmacodynamic properties 
compared with current prandial insulin products, which may offer some advantages. The 
short interval between insulin administration and the appearance of the maximal serum 
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insulin levels, and the rapid onset of action may have a beneficial effect on the control of 
post-meal glycemic excursions. Because their action wanes off more rapidly, the risk of 
postprandial hypoglycemia is decreased. Both requirements seem to be fulfilled by the 
ultrafast insulins, but their long-term safety and tolerability still remain a concern. Provided 
that larger clinical studies will confirm their positive safety and tolerability profile, these 
new technologies will become very attractive candidates for prandial insulin delivery. 
However, it should always be kept in mind that the insulin regimens need to be customized 
to each individual’s needs, in order to maximize compliance and optimize glycemic control, 
while reducing to a minimum the potential unwanted side effects like hypoglycemia and 
weight gain. Patients with diabetes need substantial psychosocial support, ongoing 
education and guidance from a diabetes team, in order to set and achieve appropriate, 
individualized management goals. 
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